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Abstract
Rebecca Charboneau
ENGINEERING A PROPHYLACTIC CAP FOR MULTI-DOSE VIAL
DISINFECTION
2020-2021
Erik Christopher Brewer, Ph.D.
Master of Science in Biomedical Engineering

Recently, multi-dose vials (MDVs) have demonstrated significant bioburden, with
randomized studies revealing bacterial contamination rates up to 27%. When the proper
protocol of disinfecting the vial diaphragm with a pre-saturated wipe is followed, MDV
bioburden is eliminated. However, when this sterilization protocol is neglected, the
susceptibility of MDV to house potential nosocomial pathogens intensifies. In this work,
the usability and effectiveness of a novel device, referred to as the Vial Cap, are
investigated to gauge the feasibility and acceptability of this device as a method of MDV
disinfection. The usability of the Vial Cap was evaluated using principle human factors
engineering (HFE) techniques to quantify the device’s ease of use, efficiency, and user
acceptance. The Vial Cap was observed to be highly accepted by the intended users as
represented by a high System Usability Scale (SUS) score. The Vial Cap was significantly
more efficient in simulated timed-based studies and the users were able to easily to operate
the device. Specific elements of the Vial Cap were evaluated to determine their individual
impact on disinfection efficacy. The minimum disinfection time, applied force, and
estimated usage were evaluated to determine improvements to the Vial Cap design.
Implementation of design recommendations from this research can produce a Vial Cap that
can enhance MDV disinfection practices and increase patient safety.
v
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Chapter 1
Introduction
1.1 Research Motivation
Nosocomial infections are a burden on hospitals with an estimated incidence of 4.5
infections per 100 hospital admissions and an annual cost of $45 billion [1]. In the United
States (US), approximately 2 million patients will develop a nosocomial infection and
about 90,000 of these patients die [1], [2]. Nosocomial infections, or hospital-acquired
infections (HAIs) are illnesses patients acquire during their stay at the hospital that were
not present at the time of admission [3]. These infections are contracted through contact
with contaminated medical equipment, airborne droplets, direct patient contact, or
improper hand washing of healthcare personnel. The presence of these infections is
unceasing with occurrence rates in 5-10% of all hospitals in Europe and North America,
and more than 40% in parts of Asia, South America, and sub-Saharan Africa [3].
Recently, multi-dose vials (MDVs) have demonstrated significant bioburden, with
randomized studies revealing bacterial contamination rates up to 27% [4]. Potentially
pathogenic microorganisms, like bacteria, viruses, and fungi, can survive and even
proliferate in and on MDV’s, increasing the risk of infection [5]. For example, outbreaks
of pyogenic abscesses occurred after diphtheria, tetanus toxoids, and pertussis (DTP)
vaccinations that were contaminated with group A Streptococcus and Staphylococcus (S.)
aureus [6].
Established disinfection protocols are utilized for injection preparation that involve
swabbing the vial’s rubber diaphragm with alcohol prior to withdraw [7]. Despite having
1

recognized disinfection protocols, studies note that poor aseptic technique due to user error
is a common cause of vial contamination that is responsible for considerable morbidity and
mortality [8], [9]. In a study conducted at a tertiary care hospital, it was observed that
98.7% (n = 307) of the vial rubber diaphragm were not swabbed with alcohol in compliance
with the current disinfection protocol [9]. Personal neglect of proper disinfection protocols
is a mounting issue with MDV preparation and administration. There is an ensuing need
for implementation of improved MDV decontamination methods that can mitigate user
errors and ensure continuous vial disinfection.
1.2 Project Scope
The aim of this research is to assess elements of an innovative device (referred to
as the Vial Cap) that curtails user error involving MDV disinfection and reduces the risk
of vial-associated nosocomial infections. All aspects of the Vial Cap prototype design have
been engineered with two basic requirements: 1) the Vial Cap must be effective and 2) the
Vial Cap must have sufficient usability. To limit vial-related infection outbreaks such as
hepatitis C, meningitis, and sepsis, the Vial Cap must be effective against pathogenic
microorganisms [6], [10]. Usability is also another important device characteristic that can
appraise the feasibility of the Vial Cap as a method of MDV sterilization. Development of
a device from a human factors-perspective can enhance aspects of the design that increase
its efficiency and usability [11], [12]. These design criteria will be explored through human
factor engineering (HFE) assessment techniques and standard engineering protocols to
determine what elements of the Vial Cap design impact its effectiveness and usability.

2

Chapter 2
Background
2.1 Nosocomial Infections
In recent years, the incidence of HAIs in the US has increased by 36% with an
annual occurrence of over 2.1 million cases [2], [13]. The World Health Organization
(WHO) estimates that approximately 15% of all hospitalized patients suffer from
nosocomial infections [14]. An HAI is defined as an infection that develops 48 hours after
hospital admission or discharge [15]. Common HAIs include hepatitis, septicemia, softtissue infections, and respiratory tract infections [15]. At-risk individuals with preexisting
conditions such as diabetes or immunosuppression and patients in Intensive Care Units
(ICUs) are 5-10 times more likely to acquire an HAI [14], [16], [17]. Risk factors that
determine HAI outbreaks depend upon the environment, condition of the patient, and
healthcare worker compliance with infection control methods [14]. Common modes of
transmission for nosocomial pathogens include contaminated medical equipment, direct
contact with an infected individual, or environmental sources such as water or body fluids.
HAIs are among the top five leading causes of death in the United States [1]. This
brings both a clinical and economic burden to hospitals and patients alike. In a study about
the impact of HAIs based on data from the Healthcare Cost and Utilization Project, it was
found that the mortality rates, length of hospital stay, and medical costs of patients with
HAIs were significantly higher compared to patients without HAIs [1]. Patients with HAIs
had costs that were 2.5-fold higher and a mortality rate that was 1.9-fold higher compared
to patients without HAIs [1]. A direct surge in a patient’s hospital stay, long term disability,
3

antimicrobial resistance, socio-economic disturbance, and mortality rates can all be related
to the occurrence of a nosocomial infection [14]. In a study of New York City hospitals, S.
aureus infections prolonged the length of stay an additional 20 days, accruing a total direct
cost of $32,100 per patient [18]. The CDC estimates that the overall annual direct costs
associated with nosocomial infections range from $35.7 to $45 billion [13]. This economic
burden drives the need for improved infection prevention programs in hospitals and
outpatient care facilities.
To date, it is uncertain what percentage of nosocomial infections are avoidable
under real-life hospital conditions. However, countless studies have proven the viability of
implementing infection control programs and HAI surveillance to reduce the infection rate
[19]–[21]. Surveillance of nosocomial infections can be used to assess the quality of care
in the hospital and the epidemiology of a nosocomial pathogen. For example, surveillance
data shows that Escherichia (E.) coli infections are found in 25% of urinary tract infections
(UTIs) while Pseudomonas (P.) aeruginosa is more commonly isolated from all major
infection sites except the blood stream [3]. The effectiveness of nosocomial infection
surveillance has proven to reduce infection rates anywhere from 14% to 71% [19].
HAI transmission from improper injection techniques and unawareness or personal
neglect of infection control measures are often the result of poor compliance with
established infection control methods [8], [14]. For example, the most preventable type of
HAI, central line-associated blood stream infections (CLABSIs), are commonly spread
through direct contact with proliferating bacteria on medical equipment and hard surfaces
that were not properly disinfected [22]. Infection control methods that can significantly
reduce HAIs include sterilization of surgical instruments, aseptic technique, hand washing,
4

isolation of infected individuals, and decontamination of high-touch surfaces [23]. In a
study conducted at an university hospital in East Germany, it was found that 12-17% of
HAIs were classified as easily avoidable and 52-55% of cases were considered avoidable
under theoretical situations [19]. Greater than 50% of device-associated bloodstream
infections are also avoidable when proper disinfection practices are followed [19].
Implementation of mandatory infection control protocols and increased healthcare worker
compliance has proven to significantly reduce infection rates and patient mortality [23].
2.1.1 Nosocomial Pathogens
The hospital microenvironment has the potential to house thousands of nosocomial
pathogens on contaminated surfaces, in the environment, and in pathogenic patients [24].
Pathogens responsible for HAIs include bacteria, viruses, and fungal spores. Specifically,
Gram-positive bacteria are the most common cause of nosocomial infections with S. aureus
being the predominant pathogenic species [25]. In a study conducted at a government
hospital in Nigeria, it was found that 80.4% of isolate microorganisms were Gram-positive
bacteria, with Staphylococcus epidermis and S. aureus being the most frequent [24]. Other
notable pathogens that can survive in dry environments include Clostridium difficile,
methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, P.
aeruginosa, and norovirus [26], [27].
The most relevant nosocomial pathogens persist on hard surfaces for months and
can even proliferate into antimicrobial resistant pathogens. Antimicrobial resistant
pathogens, like MRSA, create a serious risk for high-transmission and mortality rates
because of their resistance to disinfection [28]. Likewise, C. difficile spores found in 17%
5

of samples from infected patients have a survival rate of 44% even after bleach disinfection
[27]. The rates of nosocomial pathogen survival are a direct correlation to the 1.7 million
occurrences of HAIs per year [29]. The importance of proper disinfection procedures,
products, and compliance all play equally significant roles in the prevention of HAIs. Use
of effective and efficient disinfection practices is a viable solution to diminishing the
frequency and mortality of HAIs.
2.1.2 Disinfection Practices
The persistence of bacterial survival on hard surfaces is a concern for HAI
outbreaks. The combination of potential bacterial proliferation and poor surface
disinfection creates an opportunity to propagate nosocomial infections [30]. When proper
disinfection protocol is practiced, HAIs can effectively be eradicated from a contaminated
surface and reduce the risk of further transmission [30]. Variability due to human factors
such as user compliance, acceptance, awareness, and accessibility can affect disinfection
efficacy [30]. Studies using fluorescent markers to monitor disinfection practices have
demonstrated that some required surfaces and high-touch surfaces are not completely
decontaminated due to lack of compliance or unawareness [30], [31].
Aside from hard surfaces, reusable medical equipment can also be a mode of
transmission for nosocomial pathogens when improper disinfection occurs. For example,
unsterile injections result in 8 to 16 million new infections of Hepatitis B worldwide [32].
Vaccinations with MDVs in developing countries has been linked to high transmission of
HAIs due to poor infection control measures [14], [32], [33]. Contamination rates of 80%
have been reported for stethoscopes in a clinical setting as a consequence of inadequate
6

disinfection with alcohol pads prior to use [29]. The crucial role of wiping non-invasive
medical equipment with alcohol pads or other disinfectants is highlighted in numerous
studies by astonishing contamination rates as high as 94% [33].
The first step in successful disinfection is the selection of the ideal disinfectant. The
Environmental Protection Agency (EPA) has rigorous testing guidelines that disinfectants
must undergo to be deemed ‘effective’ for hospital-level disinfection [34]–[36].
Compliance with healthcare and cleaning staff is also another important aspect of proper
disinfection. Observational methods have shown that individual housekeeper performance
varies considerably where only 40-50% of surfaces are disinfected [37]. Continuing efforts
are needed to improve the quality and consistency of surface disinfection. The monitoring
and reporting of HAI incidence, cleaning logs, implementation of modern technologies,
and continuing education of healthcare staff have all proven to effectively reduce the
occurrence of HAIs [31], [37], [38].
2.2 MDV Contamination
MVDs typically contain antimicrobial preservatives that help prevent the growth of
potential nosocomial pathogens that remain effective for 28 days [6]. However, these
preservatives are only effective when proper vial disinfection protocol is followed [39]. It
is well documented that MDV contamination is a prominent problem in the healthcare
field. It has been reported that the rate of MDV extrinsic contamination is estimated to
range from 0% to 27% [40]. In developing countries, at least 50% of injections from MDVs
are unsafe due to poor injection practices [41]. At least 17 studies have reported MDVassociated infection outbreaks from fungi and bacteria such as S. epidermis, Candida (C.)
7

albicans, S. aureus, and hepatitis viruses [4]. Factors that may affect the sterility of MDVs
include the number of withdrawals, sterility techniques employed by healthcare personnel,
duration of storage, injection environment, and the viability of present antimicrobial
preservations [42].
When used properly, MDVs offer a cost-effective injection method in a healthcaresetting compared to single-dose vials (SDVs) [43], [44]. SDVs are preservative-free
medications that contain only a single dose of medication. They are intended for use for
one patient and should remain sealed until administration. However, SDVs have shown
contamination rates of 5.4% (n = 165) as a result of use for multiple patients [10].
Miscommunication in medical practices, inadequate training, and user negligence can all
result in SDV contamination [44].
The proper MDV disinfection protocol (referred to as the Gold Standard) generally
involves the disinfection of the vial rubber diaphragm with a pre-saturated wipe before
piercing. According to the CDC, WHO, and the Joint Commission, the Gold Standard (GS)
procedure requires that a 70% IPA wipe or swab be used to wipe the vial septum and allow
to dry for minimum 30 seconds before piercing [45]–[47]. Single-use swabs or presaturated towelettes should only be used for MDV disinfection [48]. In other countries,
national guidelines for MDV use are sometimes nonexistent, increasing the risk of
infections [49]. Often a single MDV that was improperly decontaminated can be the root
cause of an HAI outbreak, demonstrating the significance of user compliance [50].

8

2.2.1 User Compliance
A main source of MDV contamination can be related to user error in sterility
techniques when withdrawing medication from a MDV [8]. In a pilot study conducted at a
super-specialty hospital, a contamination rate of 25% were found among the sampled vials
[8]. This study aimed to evaluate the common knowledge and practices of nursing staff
regarding MDVs. It was found that the rubber diaphragms of many MDVs were never
disinfected with isopropyl alcohol (IPA) prior to use [8]. In a teaching hospital in Shiraz,
Iran, MDV contamination rates of 5.6% were attributed to lack of vigorous aseptic
precautions and enforcement of mandatory practices [40]. Although guidelines from
professional organizations like the CDC and WHO are in place for injection safety, it does
not ensure the opportunity of user-related errors is diminished [30], [50].
Other user compliance-related issues with MDV disinfection include reusing
needles or syringes, leading to serious outbreaks of HAIs including 20 million cases
annually of hepatitis B (HBV) and 2 million hepatitis C (HCV) cases [48]. Incidence of
improper preparation of the skin for an injection with a pre-saturated towelette or iodine
can also increase the chance for infection [9], [48], [51]. These poor injection practices are
vastly addressed in guidelines by the CDC and the WHO, however, issues related to MDV
disinfection are lesser addressed as there is a push to use SDVs or MDVs for one patient
[45], [51]–[53]. In developing countries, MDVs are a vital part of their healthcare system
because of they are cost-effective when used properly [54], [55]. Therefore, it is necessary
that MDV disinfection practices improve in order to reduce the opportunity for user-related
errors and allow for the continual, safe use of MDVs [56].

9

2.3 Current Solutions
2.3.1 MDV Alternatives
According to the CDC, multi-dose vials should be dedicated to a single patient
whenever possible [53]. Yet, this can be wasteful as MDVs contain more than one dose per
vial and medication costs are ever increasing [39]. SDVs are a potential solution for MDVs
to reduce medication waste in instances when an MDV is restricted to one patient.
However, prevalence of SDV extrinsic contamination has been reported with rates as high
as 5.6% with bacterial and fungal pathogens [10], [40]. SDVs are also associated with
increased wastage, manufacturing, packaging, and usage costs [54]. SDV misuse can also
result in higher rates of infection because these medications do not contain antimicrobial
preservatives.
Pre-filled syringes are a more recent development that have been adopted in
hospitals to replace SDVs and MDVs [57], [58]. Pre-filled syringes contain a single dose
of medication that requires little to no overfill volume. The advantages of pre-filled
syringes are the reduction of waste and reduced risk of contamination [57]. However, the
manufacturing and production costs of pre-filled syringes is significantly higher, ranging
anywhere from $5-30 per unit compared to $2.40 per 10-dose MDV [57]. User compliance
is still an occurring issue with the use of pre-filled syringes. In a study conducted
comparing pre-filled syringes to self-filled syringes, several patients experienced
difficulties with injecting the entire solution, difficulty activating the injection, and that the
syringe was easily damaged [59], [60].
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2.3.2 MDV Disinfection Caps
In the effort to maintain usage of MDVs, caps have been engineered to provide
protection of a vial during use and storage. Thomas et al. invented a patented device called
a ‘Reusable Vial Cap’ (Figure 1). The intended use of this device is to create a reusable
sealed closure that takes place of the crimped aluminum cap on a standard MDV [61]. This
cap is made from a resilient plastic material that clamps onto a MDV vial over the rubber
diaphragm [61]. The intentions of this design are only to replace the crimped aluminum
cap and protect atmospheric debris from collecting on the vial during storage [61].

Figure 1
Diagram of Invention US Patent no. 4,480,762

Another invention by Storar et al. was a plastic cap with a plastic hinge integrally
connected to provide closure to the vial during storage (Figure 2). A central opening on the
cap is provided to allow for a hypodermic needle to penetrate the MDV during an injection
[62]. Though both patented inventions provide physical protection for an MDV, they do
11

not provide chemical disinfection and still allow for the opportunity of

MDV

contamination when disinfection is neglected.

Figure 2
Diagram of Invention US Patent no. 5,088,612

The Vial Cap is a proposed patent-pending design, entitled ‘Reloadable Antiseptic
Vial,’ that has been engineered to be a disinfecting cap for MDVs (Figure 3) [63]. An ideal
disinfecting cap for MDVs would provide continuous chemical disinfection, a physical
barrier against pathogens, and be easy and efficient to operate. The Vial Cap incorporates
these design criteria into integral cap design that provides continuous sterilization of an
MDV during use and storage. The patent-pending design proposed two variations of the
device related to its reusability. The first proposal is a sterile, single-use cap design that is
made from a nonporous plastic [63]. The second proposed design is a reusable cap that
disinfects a MDV vial between uses by housing a replaceable pre-saturated sponge or
housing a permanent saturated sponge that has a prescribed maximum number of uses [63].

12

The proposed usage and design from Provisional Patent no. 62/496,676 were used in
reference for the current iteration of the Vial Cap design.

Figure 3
Patent-Pending Design of the Vial Cap

2.4 Vial Cap Design
2.4.1 Human Factors Engineering
With the advancement of technologies in medicine, important considerations for
patient safety while maintaining efficiency and effectiveness are at the forefront of
engineering design [64]. HFE is a discipline of engineering that seeks to support device
and system development with the central focus based around the user [65]. HFE design is
devoted to optimizing the design of a device that improves device performance and user
safety [65]. Benefits of integrating HFE design include reduced error rates, decreased
13

training time, increased ease of use, improved task performance, and enhanced patient and
user satisfaction [11].
HFE best practices were utilized throughout the design validation of the current
Vial Cap prototype. User research played an integral role in the Vial Cap design because
there is an evident need for a more efficient method of MDV disinfection that reduces the
opportunity for user-errors [52], [66], [67]. Usability testing was conducted to allow for
the intended users to interact with the current Vial Cap prototype. Usability testing is a
formal method of systemically observing users that allows for the ease of use, ease of
learning, efficiency, and user appeal to be assessed [11], [12], [68]. Utilizing these HFE
techniques during the Vial Cap design process can be used to enhance future device
performance and improve user safety and satisfaction [65], [68], [69].
2.4.2 Design Criteria
The design criteria of the Vial Cap can be summarized by two requirements: The
Vial Cap must be effective and have sufficient usability. An effective Vial Cap is defined
by its ability to disinfect nosocomial pathogens with comparable metrics to pre-saturated
wipes [70]. Without achieving the minimal disinfection requirements of pre-saturated
wipes, the Vial Cap will not be an approved device for use [70], [71]. The other important
aspect of interest is usability. Usability metrics such as learnability and efficiency can help
gauge the Vial Cap’s acceptance and feasibility for use in a hospital setting.

14

2.4.3 Design Iterations
The Vial Cap design was influenced by the provisional patent to provide consistent
disinfection of MDVs during use and storage that allows for immediate medication
withdraw after cap removal. The basics of the Vial Cap design incorporate a physical
barrier made from polylactic acid (PLA), a ridge plastic used in 3-dimensional (3D)
printing. Housed inside the cap is a cotton sponge saturated with 70% IPA to act as a
chemical disinfectant. The progression of the Vial Cap design reflects evolving HFE design
considerations for the intended users and operation of the device.
3D printing was used as the iterative prototyping method for the scope of this
research. 3D Printing is a manufacturing method in which objects are made by depositing
materials in layers to produce a 3D object [72]. This additive manufacturing method allows
for the rapid and cost-effective development of products [72]–[74]. A Creality Ender 3 Pro
equipped with Inland PLA and PLA+ filament was used for cap prototypes. A ridge,
nonporous plastic filament was selected for the Vial Cap design because of its ability to
withstand any damage during storage and use. The key printing parameters can be found
in Table 1 below:
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Table 1
3D Printing Parameters
Parameter

Input

Infill

100%

Number of Shells

4

Layer Height

0.2 mm

Extruder Temperature

210°C

Printing Speed

60 mm/s

The Vial Cap design history can be defined with four generations of 3D printed
prototypes. The first-generation design of the Vial cap was created to gain an understanding
of the vial dimensions (Figure 4). This first design was engineered to seal the diaphragm
of the vial from the environment, similar to patented vial cap designs [61], [62]. The design
also included ridges on the outside of the cap to provide traction for user ease of use. This
design did not allow for any pre-saturated sponge to be housed in the cap.
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Figure 4
First-Generation Vial Cap Design

B

A

Note. A) Vial Cap render. B) Modeling of first-generation Vial Cap.

Second-generation cap design iterations included an increased cap height that
allows for a pre-saturated sponge to be housed (Figure 5). Complications with this cap
design that prohibited its success were issues related to pressing the cap on to seal it. There
is no mechanism that prevents the user from pressing the cap flush with an MDV, and as a
result the generated pressure would cause IPA to expel from the sponge.
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Figure 5
Second-Generation Vial Cap Design
A

B

Note. A) Vial Cap render. B) Modeling of second-generation Vial Cap.

For the third-generation cap design, the height was decreased, and an inner ridge
was incorporated into the cap design to house the sponge (Figure 6). The inner ridge served
dual purposes: to act as a ledge to house the sponge and prevent the user from forcing the
cap on too far. However, a significant usability flaw with this design is the potential for
cap misplacement during use.
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Figure 6
Third-Generation Vial Cap Design
A

B

C

Note. A) Vial Cap render. B) Modeling of third-generation Vial Cap. C) Birds-eye view of
the inner ridge of the Vial Cap.

2.4.4 Current Vial Cap Design
The current Vial Cap design, also considered the fourth-generation design,
incorporates an integral hinge design that resolves the issues of the previous cap designs
(Figure 7). The hinge design allows for the cap to easily open during an injection while
remaining attached to the MDV. The cap maintained the inner ridge design to house the
sponge and prevent any issues with sealing the cap. Additionally, a tab was added to the
cap design to enhance user intuition and efficiency during cap operation.
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Figure 7
Fourth-Generation Vial Cap Design
B

A

C

D

Note. A) Vial Cap render, side-view. B) Vial Cap render, open cap C, D) Modeling of
fourth-generation Vial Cap.

HFE design techniques were used to engineer this optimal cap design that
incorporates all aspects of the other designs to improve overall usability and efficiency
(Figure 8) [11], [75]. For the focus of this research, the fourth-generation cap design was
used to assess the effectiveness and usability of the Vial Cap.

Figure 8
Vial Cap Design Generations
B

A

Note. A, B) Modeling of Vial Cap design generations.
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Chapter 3
Research Aims
This work focuses on assessing different elements of the Vial Cap prototype design
that will achieve the required levels of disinfection and have acceptable usability. Design
requirements associated with disinfection and usability are the main motivators of this
research because they summarize the main issue with MDV contamination: user error with
the current disinfection protocol. Therefore, determining the cap elements that maximize
effectiveness and usability can ensure the device is more readily accepted by the intended
users for implementation in a hospital setting.
The first objective was to assess the usability of current Vial Cap prototype to
understand what cap elements allow the device to be efficient to operate, easy to use, and
yield high user acceptability. Human factors methods were used to design and execute a
usability assessment of the Vial Cap to reveal any design flaws and receive user feedback
about the current prototype design [76]. Measurable outcomes such as the error rate,
completion rate, and timed operation were quantified to determine which elements of the
current design can be improved.
The second objective was focused on determining the design elements that enhance
the sterilization capabilities of the Vial Cap. ASTM Standard E2362-15, which defines a
standard method to evaluate the hard surface disinfection of pre-saturated towelettes, was
modified for testing the Vial Cap’s effectiveness. Instead of disinfecting a hard surface, the
test specimen were cultured on the rubber vial septum for disinfection [71]. The selected
test specimen were E. coli, S. aureus, and P. aeruginosa due to their virulence as common
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nosocomial pathogens [78], [79]. Aspects of the Vial Cap design such as disinfection time,
applied force, and sponge saturation were studied using to determine future cap design
iterations and estimate standards for labeling.
The specific aims of this project are as follows:
Specific Aim 1: Assess the acceptability of the Vial Cap prototype based on a usability test
designed to measure its ease of use, efficiency, and user satisfaction.
Specific Aim 2: Evaluate design elements of the Vial Cap prototype and their impact on its
bactericidal efficacy to implement into future design iterations.
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Chapter 4
Usability Assessment of the Vial Cap
4.1 Introduction
Human factors engineering is the application of knowledge about human abilities
(physical, intellectual, sensory) and limitations to the design and manufacturing of devices,
systems, and organizations [11]. HFE involves the combination of behavioral studies and
engineering principles in device design and evaluation [11]. One of the main goals of HFE
design is usability. Usability is defined as the extent to which a product can be easily used
by the intended users to achieve certain goals with effectiveness, efficiency, and
satisfaction [80], [81]. Device design without the use of HFE techniques can increase the
risk of injury, training time, decrease the ease of use, and diminish user satisfaction [11].
The Harvard Medical Practice Study showed that human error is the cause of up to 69% of
injuries to patients related to medical devices [82]. Hence, it is important that HFE-based
design and assessments are utilized to evaluate usability aspects of the Vial Cap design.
A usability test was designed to test the ease of use, efficiency, and user satisfaction
of the Vial Cap prototype. Efficiency was measured by comparing how long it takes the
user to disinfect an MDV using the Vial Cap compared to the current protocol (referred to
as the Gold Standard). It has been cited that the current protocol is most susceptible to usererror during emergency situations as it can pose a serious time-threat [60], [64], [69].
Therefore, it was determined important to compare the Vial Cap’s disinfection efficiency
to the Gold Standard in a time-sensitive situation to see if it would have an improved
performance. The ease of use was quantified through observing the participant’s ability to
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operate the Vial Cap when handed the device. This test can determine if the Vial Cap design
is intuitive and will reveal any design flaws [83]. At the conclusion of usability testing, a
System Usability Scale (SUS) questionnaire was administered to assess the perceived ease
of use and user acceptance [76], [84], [85]. User acceptance has a high impact on product
design requirements, indicating the significance of evaluating the user’s opinions at the
conclusion of testing [86].
4.2 Materials and Methods
4.2.1 Human Study: Sample Size and Setting
The usability assessment was performed with an approved IRB protocol (PRO2021-271) from the Rowan University Institutional Review Board, Glassboro, New Jersey,
US. Participants were selected through a volunteer-basis recruitment process at Cooper
University Hospital, Camden, New Jersey, US. A total of 13 participants were selected
based on the following inclusion criteria: 1) experience with MDVs, 2) nurse at Cooper
University Hospital, and 3) speak and write English fluently. 13 participants allowed for
multiple rounds of testing to be performed to allow for design and procedural iterations. It
has been shown that after the first five participants, about 80% of the usability issues are
identified, making it important to have a sample size greater than five [87].
Usability testing was performed with one participant at-a-time to prevent any
external bias from others. The study duration for the participants is 30 minutes per
participant. Upon arrival to the testing session, participants were to have completed the
informed consent form so that they are aware of the circumstances and any associated risks
with the study.
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4.2.2 Ease-of-Use Test
The first task of the usability assessment is simulating drawing-up medication from
an MDV that has the Vial Cap on it. A sterile syringe with no needle was used, and the
MDV did not contain any liquid medication. This serves to determine the ease of use based
on first-hand experience and simulated usage with the Vial Cap. The following flow
diagram outlines the subtasks that the participants will have to complete to operate the Vial
Cap successfully:

Figure 9
Subtask Flow Diagram: Ease of Use Test

The measurable outcomes of this test will be based on the completion of each
subtask. The error and completion rates can be used to determine the overall ease of use of
the Vial Cap [76]. The completion rate will be based on the success or failure of each
subtask. The completion rate (C) is measured as a percentage value for success (coded as
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100%), partial success (coded as 50%), or failure (coded as 0%) [80]. Partial success is
selected when a participant performs the wrong action but can complete the subtask after
another attempt without input from the investigator. The error rate (E) is determined by a
binary system: the user encountered an error (1 = yes) or did not (0 = no) [81].
4.2.3 Efficiency Test
The second test of the usability assessment involves a comparison of usage time
between the Gold Standard and the Vial Cap. A timed simulated medication withdraw will
be performed by the participants using the Vial Cap and Gold Standard method. For this
timed task, the participants will be told to complete the medication withdraw as if it were
a time-pressed situation. This task will be completed and timed for each MDV disinfection
method. The timed results will provide a direct comparison of efficiency between each
disinfection method.
4.2.4 User Acceptance
To quantify the user satisfaction and acceptance of the Vial Cap, a SUS
questionnaire will be administered at the conclusion of testing. The SUS questionnaire is
constructed of ten Likert scale questions and one adjective rating scale question. The Likert
scale questions probe the user to analyze the positive and negative aspects of the design.
The answer options are on a scale from one to five with one being ‘Strongly Disagree’ and
five being ‘Strongly Agree.’ The questionnaire is administered immediately after the
participants complete testing. The calculated results will provide a SUS score from 0 to
100, with 100 indicating perfect usability [76].
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4.2.5 Data and Statistical Analysis
The task completion rate (C) is measured as a percentage value for success (coded
as 100%), partial success (coded as 50%), or failure (coded as 0%) for each subtask [80].
Equation 1 was used to calculate the completion rate where ||t|| denotes the number of
subtasks, 𝐶(𝑠𝑢𝑐) denotes the number of successes, and 𝐶(𝑝𝑎𝑟) denotes the number of
partial successes [80]:
𝐶(𝑡) =

∑𝑠𝑢𝑐∈𝑡 𝐶(𝑠𝑢𝑐)
||𝑡||

∑𝑝𝑎𝑟∈𝑡 𝐶(𝑝𝑎𝑟)

+(

||𝑡||

∗ 0.5)

(1)

The error rate (E) is also determined by a binary system: the user encountered an
error (1 = yes) or did not (0 = no) when completing each subtask [81]. Equation 2 was used
to calculate the error rate where ||t|| denotes the number of subtasks and e is the number
of errors:
𝐸(𝑡) =

𝑒
||𝑡||

(2)

The efficiency was determined by comparing the task duration (T) or the total time
taken to achieve a particular task at hand [80]. The task duration was measured in seconds
and the average time for both disinfection methods were compared.
To calculate the SUS score, the sum was taken from each question (n = 10). Each
question’s score contribution will range from 0 to 4. In the questionnaire, questions 1, 3, 5,
7, and 9 the score contribution is the scale position minus 1 [88]. For questions 2, 4, 6, 8,
and 10, the contribution is 5 minus the scale position [88]. The contributions are summed
and then multiplied by 2.5 to obtain the overall score (Equation 3) [80]. The SUS score
will range from 0 to 100.
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𝑆𝑈𝑆 = 2.5 × [ ∑5𝑛=1(𝑈2𝑛−1 − 1) + (5 − 𝑈2𝑛 )]

(3)

An adjective rating scale will also be included at the end of the questionnaire. The
variability was determined by calculating the standard deviation or the 95% confidence
interval (CI). The level of significance used in this study will be 0.05. One-way analysis of
variance (ANOVA) was used to determine the statistical significance from efficiency
testing. A one-sided t-test was used to determine the statistical significance of the SUS
score compared to the ‘excellent’-rated score [81].
4.3 Results
4.3.1 Ease of Use
The ease of use of the Vial Cap was quantified based on the successful completion
of each subtask required to operate the Vial Cap (Figure 10). Subtask 1 was the most
difficult with participants having an 84.62% completion rate. One error occurred for two
participants at the first step of the Vial Cap operation where participants believed the needle
would be pierced through the cap as opposed to flipping it open. However, the two
participants were able to successfully figure out how to complete after this error and
considered to be partial completion. This brings the total for Subtask 1 to be 100% after
overcoming the two errors that occurred. Subtasks 2 and 3 had 100% completion rates.
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Figure 10
Task Success Distribution for Ease of Use Testing

Note. Data is representative of each subtask completion rates where n = 13 is the number
of participants completing each subtask of the Vial Cap operation.

4.3.2 Efficiency
The Vial Cap’s medication withdraw time when compared to the GS was
significantly (p = 0.0000279) faster for MDV disinfection. When comparing the minimum
disinfection requirements of an MDV during an emergency, the Vial Cap is likely to be
8.47 ± 3.07 s faster than the GS procedure (mean difference ± 95% confidence interval).
The average time to simulate withdrawing medication using the Vial Cap was 7.62 ± 0.37
s and the GS was 16.09 ± 0.60 s. The additional step of sealing the Vial Cap after
medication withdraw was still significantly (p = 0.0241) faster than the GS protocol. The
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entire Vial Cap process was likely to be 4.18 ± 3.26 s faster than the GS procedure. The
entire Vial Cap process took an average time of 11.91 ± 0.42 s.

Figure 11
Vial Cap Efficiency Test Results

Note. Data is representative of the mean ± standard deviation where n = 13 for each timed
disinfection process. * (p < 0.05); *** (p < 0.001).

4.3.3 User Acceptance
The results of the Vial Cap’s SUS were a score of 95.19 ± 5.63, a high result
compared to the average score of 68 (Figure 12) [87]. 23.08% of participants rated the Vial
Cap as ‘best imaginable’ and the other 76.92% described the design as ‘excellent’ when
asked to choose an adjective to describe the device. When comparing the Vial Cap’s SUS
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score to other metric scales for interpreting usability, the Vial Cap can be described as
‘excellent’ on the adjective rating scale (Figure 12) [88]. The desired outcome of the SUS
was a score equal to or greater than ‘excellent’ (SUS score of 85) to provide supporting
evidence of user acceptance. The one-sided t-test revealed statistical significance
(p = 0.000014) that the Vial Cap’s score is higher than the correlating score for ‘excellent.’

Figure 12
SUS Questionnaire Results

Note. A) Vial Cap SUS results where data is representative of the mean ± standard
deviation where n = 13 for total participants. B) HFE scale for comparison of adjective
ratings, acceptability scores, and grading scales in relation to SUS scores [88].
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Participant feedback was collected the usability study to provide insight into their
acceptance of the Vial Cap. A summary of the frequent comments can be found in Table
2. Important comments to address include comments received about the design such as “it
was bulky” (n = 6) and that the Vial Cap should be reusable (n = 7) and “needs a way to
track uses.”

Table 2
IRB Study Participant Comments
Comment

Comment

Positive Tone

Frequency

Negative Tone

Frequency

Efficient and easy to use

13

Cap is bulky

6

Vial Cap did not get in the way

Vial Cap is not
10

3

during injections

stationary/gets in the way

The Vial Cap should be made

There needs to be a way to
12

7

from a ridge material

keep track of uses

Provides reassurance that a vial

Cap needs to remain
3

2

is disinfected and protected

stationary during injections
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4.4 Discussion
The usability assessment performed in this work is a useful HFE technique that
provides insight to a device’s usability and user acceptance [83]. Evaluation of the Vial
Cap’s ease of use, efficiency, and user satisfaction revealed flaws with the current design
and insight into the device’s potential as a method of MDV disinfection. From ease of use
testing, the only task that created difficulty for participants was Subtask 1 which involved
opening the Vial Cap to reveal the rubber diaphragm for an injection. The error that
occurred (n = 2 participants) might be related to user practice or the need for design
improvements [76]. These errors provide diagnostic information related to the device
design, the user-interface, and perceived usefulness of the Vial Cap [81]. From a design
perspective, the ‘tab’ meant for flipping the Vial Cap open could be increased in size to
indicate the cap should be opened before withdrawing. Once the Vial Cap was successfully
opened, the other subtasks were straightforward and yielded 100% completion. The
minimal error rate (n = 2) encountered during Vial Cap operation can support the claim
that the ‘Vial Cap is easy to use.’ The results from this study demonstrated an effective
operation of the Vial Cap, providing supporting evidence that the device is easy to use [76],
[89].
Efficiency is another important element of a medical device that most often directly
or indirectly related to cost, safety, and satisfaction [69], [90]. When assessing the Vial
Cap, it needs to disinfect a vial as or more quickly than the GS protocol to be accepted by
the intended users [75], [91]. Considering the minimum steps for MDV disinfection
(disinfecting the vial diaphragm and withdraw), the Vial Cap was significantly (p < 0.001)
faster than the GS procedure. This significant decrease in disinfection time can be the
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determining factor in an emergency [51], [64]. Even when adding the step of recapping,
the Vial Cap was still significantly (p < 0.05) faster than the GS procedure. These results
provide evidence that the Vial Cap can potentially reduce the opportunity for user-related
errors by increasing the efficiency of MDV disinfection.
User acceptance is another critical element of medical device design and validation
because without user approval, a device would not be successfully implemented in a
healthcare-setting [92]. The average SUS score was 95.19, correlating to ‘excellent’
satisfaction and usability on the adjective rating scale [84], [87], [88]. Mounting evidence
supports the validity and reliability of the SUS score in extrapolating a device’s usability
and user acceptance [81], [87], [93]. The reported SUS score can be interpreted as the
users’ expressing their acceptance and satisfaction with the Vial Cap [87]. Items Q3 and
Q7 on the SUS questionnaire stated that the system was “easy to use” and users “would
learn to use this system very quickly.” All 13 participants replied “Strongly Agree” to these
items, representing satisfaction and likeability of the Vial Cap. The ability of participants
to overcome an error during cap operation also supports the reliability of the SUS score to
quantify user acceptance.
Comments that were recorded during testing pertained to positive and negative
aspects of the Vial Cap design. The comment that had the highest frequency (n = 13) was
that the Vial Cap was “easy and efficient to use.” Participants were accepting and
enthusiastic about the Vial Cap saying it would “provide reassurance of MDV disinfection”
and “solves convenience issues with vial disinfection.” Considerations for Vial Cap design
from comments included making the cap less “bulky” and that the cap “gets in the way
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during injections.” It was observed that the Vial Cap would rotate when inverted for
withdraw and could become a potential obstruction during use. This design flaw could be
resolved by using a flexible material, such as thermoplastics like urethane (TPU), that can
more easily grip the MDV neck and resist rotation when inverted. The Vial Cap’s bulkiness
can be minimized by reducing the overall cap height and thickness.
When engineering the Vial Cap, there are considerations for whether the Vial Cap
should be reusable or single-use. The participants were asked their preference on this
subject and it was found that 46% of participants would prefer the Vial Cap to be singleuse while 54% of participants would prefer a reusable device (Table 3).

Table 3
Single-Use vs Reusable Poll Results
Single-Use Device Reusable Device
6

7

There are more design considerations for making the Vial Cap a reusable device.
The most important concern from the participants was a way to track the cap’s reusability.
Potential design solutions to track the cap’s usage would be a color-coded label that is
placed on the Vial Cap that corresponds to its expiration date. Or the Vial Cap could have
a built-in dial that allows the user to increase the number as the cap is used. The reusability
of the Vial Cap will be dictated by its ability to disinfect at the final stage of prototyping.
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4.5 Conclusion
Usability is an important aspect of medical device design to ensure device
reliability, safety, and performance for both the user and patient [94]. HFE-based design
considers design aspects such as ease of use, safety, efficiency, and learnability [94]. These
HFE-based design metrics were quantified using a usability assessment for the Vial Cap
prototype. Results revealed that the Vial Cap prototype had high usability, acceptability,
and learnability. A high average SUS score can be related with a high completion rate and
a significant reduction in disinfection time. User acceptance observed during testing
provides supporting evidence of the feasibility of the Vial Cap as a new method of MDV
disinfection.
Results from usability testing can act to improve the Vial Cap’s operation and
increase its acceptance. As future iterations of the Vial Cap are produced, the methods
outlined in this work can be used to continue testing the device’s usability. FDA guidelines
of usability testing require usability testing to demonstrate a device can be used by the
intended users without serious harm [90], [95]. The results from this study have
demonstrated the ability of the intended users to operate the Vial Cap successfully and
safely. Furthermore, future usability studies conducted with an improved Vial Cap design
can continue progress the usability and acceptability of the device for use in a hospital
setting.
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Chapter 5
Vial Cap Effectiveness
5.1 Introduction
The characterization of the Vial Cap effectiveness is an important element in the
cap design because it is the main function of the device. For successful implementation of
the device in a hospital setting, the cap must meet the required efficacy standards of similar
products such as pre-saturated towelettes [96]. Engineering and regulatory standards set by
organizations such as the Environmental Protection Agency (EPA), Food and Drug
Administration (FDA), Centers for Disease Control (CDC), and American Society for
Testing and Materials (ASTM) require a minimum level of disinfection for a device to
permitted on the market [35], [36], [70], [97], [98].
ASTM Standards E2362-15, E2896-12, and E2967-15 outline specific methods for
characterizing the bactericidal efficacy of pre-saturated towelettes used for surface
disinfection. The methods outlined by these standards are relevant to surface contamination
in hospitals and are reproducible procedures that can be used for testing pre-saturated
towelettes and similarly, the Vial Cap [70], [99], [100]. These standard testing procedures
were adapted for the Vial Cap by using an MDV vial as the ‘hard surface’ for disinfection.
Design elements of the Vial Cap, such as disinfection time, applied force, and sponge
saturation were tested independently to determine their impact on the Vial Cap’s
effectiveness. Consideration of these conditions can act to improve the Vial Cap’s current
design while learning insightful information about the device’s prescribed use. Gramnegative and Gram-positive bacteria were used as the test specimen because of their
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prevalence as virulent nosocomial pathogens [101]. ASTM Standard E236-15 also
recommends testing both species of bacteria to recreate a contaminated surface in a hospital
setting [70], [102]. Results of testing will provide an understanding of design elements that
improve the Vial Cap’s effectiveness to be implemented in future design iterations.
5.2 Materials and Methods
5.2.1 Bactericidal Efficacy of Vial Cap
S. aureus (ATCC 35556), P. aeruginosa (ATCC 10145), and E. coli (D31) were
chosen as Gram-positive and Gram-negative species as the nosocomial pathogens [70],
[99], [102]. The bacterial species selected are also relatively resistant to drying, allowing
for ≥108 colony forming units (CFUs) on each dried carrier. Organisms grown from frozen
stocks were incubated (Incu-Shaker Mini, Benchmark) at 37 ± 1°C and at 225 rotations per
minute (RMP) for 18 ± 2 h in 3 mL of Luria-Bertani (LB) (Miller) broth. Clear, borosilicate
glass, pre-assembled MDVs (2 mL volume, 13 mm height) with a butyl stopper and
aluminum seals were used as the test carriers. This overnight culture was then diluted to
10-3 CFU/mL for application onto test carrier. Before use, each vial was autoclaved to
ensure sterility for testing.
Working under sterile test conditions, a calibrated positive-displacement pipette
(VWR, RAININ) was used to place 10 µL of the test diluted bacterial suspension on the
rubber diaphragm of each vial [70], [99]. Once inoculated, the vials were transferred to a
37 ± 1°C incubator for 30 min to dry the bacterial suspension. While the bacterial
suspension was drying, the Vial Caps for testing were prepared. Each 3D printed Vial Cap
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was soaked with 70% IPA to disinfect prior to use. Uniform 1 x 1-in cotton sponges (VWR)
were cut with a pair of sterile scissors to be used in the Vial Cap.
After the bacterial suspension has dried on the test vials, the Vial Caps were loaded
with 70% IPA (70% Lab Grade, Ward’s Science) and applied on the test vial under specific
conditions of time, force, and sponge saturation. At the conclusion of testing time, the Vial
Cap was removed from the test vial and the rubber diaphragm was swabbed with a sterile
cotton swab moistened with Dulbecco’s phosphate buffered saline (PBS) (pH 7.4, VWR).
The collected specimen was placed in 2 mL of LB Broth that was vortexed (Mini Vortexer,
VWR) for 5 s and incubated overnight (24 h) at 37 ± 1°C, 225 RPM. Following overnight
incubation, the absorbance was measured at 600 nm using a spectrophotometer
(GENESYS 10S UC-Vis, Thermo Scientific) and serial dilutions (up to 10-4) were
performed for petri-dish plating. 20 µL of the 10-3 and 10-4 dilutions were plated onto LB
agar (Difco) plates using sterile glass beads to spread the samples. LB agar plates were
held upright at room temperature (RT) for 30 ± 2 min prior to plating. Samples were
incubated (My Temp Mini, Benchmark) at 37 ± 1°C for 24 ± 2 h and counted for any CFUs
to quantify effectiveness.
The efficiency of recovery of dried test bacteria from the vials was assessed by
placing 10 µL of the test inoculum onto a vial, allowing it to dry at 37 ± 1°C for 30 min,
and eluting it immediately. This sample was used as the ‘positive’ or ‘untreated control’ to
determine the baseline for calculating the log10 reduction values after Vial Cap application
[70], [99], [102]. Randomly selected vials were tested for sterility, deemed as the ‘negative
controls’, to ensure routine quality control of all sterile procedures.
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5.2.1.1 Design Test Conditions. Disinfection times from 5-300 s were employed
to determine the minimum disinfection time that produces consistent disinfection. A range
of forces from 0-5 Newtons (N) generated by placing weights on the Vial Cap were used
to determine the importance of an applied force. Sponge saturations from 0-100% were
tested to determine the threshold of disinfection for correlation to cap usage. Sponge
saturation was loaded into the Vial Cap using a scale (VWR) to precisely measure the IPA.
5.2.2 Passive Evaporation
The impact of passive evaporation of the Vial Cap prototype was simulated through
long-term storage of the cap. Dry weight measurements were taken of the assembled Vial
Cap (0% sponge saturation) and MDV with a calibrated scale (precision ± 0.01 mg, Mettler
Toledo). The Vial Cap was loaded with a fully (100%) saturated sponge and immediately
placed on an MDV. The 100% saturated Vial Cap and MDV were then weighed and
recorded as the day 0 measurement. The Vial Cap remained sealed while weight
measurements were taken periodically over a period of 19 days to simulate long-term
storage. Six MDVs were stored at ambient room conditions and another six vials were
stored at 37°C and 100% room humidity (RH) in an incubator (NU-8500, NuAire) to
simulate extreme conditions.
5.2.3 Simulated-Usage
Simulated-usage testing was conducted to determine the cap’s evaporation as a
function of usage. Dry weights were first taken of the assembled Vial Cap (0% sponge
saturation) and MDV. The Vial Cap was loaded with a fully (100%) saturated sponge and
immediately placed on an MDV. The 100% saturated Vial Cap and MDV were then
weighed and recorded as the 0-use measurement. To begin the experiment, the Vial Cap
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first remained sealed for 5 min and then was removed for 30 s. The Vial Cap was recapped
after the 30 s and the weight was recorded. This process was repeated for 60 mins to create
a model of evaporation on a per-use basis. MDVs were tested at ambient room conditions
and at 37°C and 100% RH to simulate extreme conditions.
5.2.4 Data and Statistical Analysis
Data analysis for petri-dish plating was analyzed as described in ASTM Standards
E2362-15 and E2896-12 [70], [99]. The CFU per carrier was calculated by first counting
the present colonies using ImageJ, the Colony Counter plugin. Equation 4 describes the
CFU/carrier equation where 10-x is an example of a serial dilution [70].
[(𝑎𝑣𝑔.𝐶𝐹𝑈 𝑓𝑜𝑟 10−𝑥 ) × (𝑉𝑜𝑙.𝑜𝑓 𝑏𝑟𝑜𝑡ℎ)]

𝐶𝐹𝑈⁄𝑐𝑎𝑟𝑟𝑖𝑒𝑟 = [(10−𝑥 ) × (𝑉𝑜𝑙.𝑝𝑙𝑎𝑡𝑒𝑑) ×(# 𝑜𝑓 𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠 𝑝𝑒𝑟 𝑠𝑒𝑡)]

(4)

The log density (LD) of each positive control carriers was calculated to determine
if an adequate amount of bacteria remained viable after drying (Equation 5) [70].
𝐿𝐷 = 𝑙𝑜𝑔10 (𝐶𝐹𝑈⁄𝑐𝑎𝑟𝑟𝑖𝑒𝑟)

(5)

The log reduction (LR) of each carrier was calculated to determine the reduction of
bacterial growth after application of the Vial Cap. Equation 6 describes the LR equation
where 𝑙𝑜𝑔10,𝑝𝑜𝑠 is the LD of the positive control and 𝑙𝑜𝑔10,𝑐𝑎𝑟 is the LD of the selected
carrier [100].
𝐿𝑅 = 𝑙𝑜𝑔10,𝑝𝑜𝑠 − 𝑙𝑜𝑔10,𝑐𝑎𝑟
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(6)

Equations 7-8 describe the necessary calculation to determine the CFU/mL for a given
bacterial suspension (EC, PA, SA) based on the measured absorbance (𝑂𝐷600 ) [103].
𝐶𝐹𝑈⁄𝑚𝐿𝐸𝐶 = 𝑂𝐷600 × (1 × 109 )

(7)

𝐶𝐹𝑈⁄𝑚𝐿𝑃𝐴,𝑆𝐴 = 𝑂𝐷600 × (5 × 108 )

(8)

The effectiveness of the Vial Cap can be quantified as a percentage to represent the
number of bacteria that were eradicated from the test carrier [99]. For example, 100%
effectiveness represents 0 CFUs remaining on the test carrier. Equation 9 outlines the
calculation for effectiveness where 𝐶𝐹𝑈⁄𝑚𝐿𝑐𝑎𝑟 represents the CFU/mL of a test carrier
and 𝐶𝐹𝑈⁄𝑚𝐿𝑝𝑜𝑠 represents the untreated control.
(𝐶𝐹𝑈⁄𝑚𝐿

)

𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 (%) = 1 − [(𝐶𝐹𝑈⁄𝑚𝐿 𝑐𝑎𝑟 )]
𝑝𝑜𝑠

(9)

The sponge saturation of the Vial Cap can be calculated as a percentage to represent
the remaining disinfectant in the Vial Cap after a period of time or uses. Equation 10
describes the calculation to determine the sponge saturation where the 𝑊𝑡 is the sample
recorded at a specific time interval and the 𝑊𝑠 is the weight at 100% saturation or timepoint
zero.
𝑆𝑎𝑡𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (%) =

𝑊𝑡
𝑊𝑆

(10)

ANOVA was used at a 95% level of significance to test statistical differences
between disinfection time, force, and sponge saturation variables. The variability will be
determined by calculating the standard deviation for all test conditions.

42

5.3 Results
5.3.1 Bactericidal Efficacy of Vial Cap
To determine the basis of each design requirement of the Vial Cap, the baseline
design conditions first had to be quantified in terms of bactericidal efficacy. The baseline
test conditions were as follows:

Table 4
Baseline Test Conditions
Test Condition

Value

Disinfection Time

300 s

Sponge Saturation (%)

100%

Applied Force

0N

The efficacy of the Vial Cap under these conditions was first measured through an
absorbance measurement of turbidity. It was determined that the Vial Cap was 100%
effective against E. coli (± 2.59%) and P. aeruginosa (± 0.69%) and was 95.8% effective
against S. aureus (± 19.34%) (Figure 13).
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Figure 13
Baseline Turbidity Results

Note. Data is representative of the mean ± standard deviation where n = 10 for each test
specimen.

To quantify the disinfection ability of the Vial Cap in accordance with ASTM
E2362-15 and E2896-12, the quantitative plate method (QPM) was employed. There was
a 6.08 ± 3.24 log10 reduction in E. coli, 7.97 ± 2.31 log10 reduction in P. aeruginosa, and
4.82 ± 3.58 log10 reduction in S. aureus (Figure 14). These results can be converted into
corresponding sterilization values to understand the Vial Cap’s disinfection abilities at
baseline conditions. There was a 70.08 ± 36.70% total sterilization of E. coli, a 57.53 ±
42.97% reduction of S. aureus, and 87.47 ± 25.09% reduction of P. aeruginosa. The Vial
Cap produced a better reduction in the Gram-negative bacteria than the Gram-positive S.
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aureus. The maximum log reduction, represented by zero CFUs, is 7-9 log10 reduction
depending on the test specimen.

Figure 14
Baseline QPM Results

Note. A) Bacterial log10 reduction of the Vial Cap. The mean is represented by the middle
crossbar while the error bars are representative of ± 2 standard deviations from the mean
for n = 10 for each test specimen. The yellow heighted region indicates the range of
maximum log10 reductions that can be achieved based on n = 6 positive samples. B)
Efficacy conversion from QPM testing.

5.3.1.1 Disinfection Time. Preliminary turbidity testing was performed at a variety
of disinfection times to estimate the Vial Cap’s prescribed disinfection time for use.
Disinfection times 5 s, 10 s , 30 s, 60 s, and 120 s were tested and compared to the baseline
disinfection time of 300 s. It was observed that 120 s performed comparable to the Vial
Cap at 300 s. There was a 4.91% decrease in effectiveness at 120 s for S. aureus compared
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to 300 s (Figure 15). The consistency of disinfection achieved at 120 s prompted further
testing with QPM at 120 s to determine if this time can achieve comparable sterilization.

Figure 15
Disinfection Time Turbidity Results

Note. Data is representative of the mean ± standard deviation where n = 3 for 5s, 10s, 30s,
and 60s groups, n = 5 for each 120s group, and n = 10 for each 300s group.

QPM results for a disinfection time of 120 s showed there was a 4.95 ± 3.29 log10
reduction in E. coli, 6.42 ± 2.98 log10 reduction in P. aeruginosa, and 4.54 ± 2.98 log10
reduction in S. aureus (Figure 16). This is a 21.77% ± 20.11% decrease in efficacy for E.
coli, 3.47% ± 21.20% decrease for S. aureus, and 4.13% ± 16.47% decrease for P.
aeruginosa compared to 300 s. The variability and reduction of sterilization at 120 s
indicate that efficacy is compromised for a faster disinfection time.
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Figure 16
Disinfection Time QPM Results

Note. A) Bacterial log10 reduction of the Vial Cap at 120s and. The mean is represented by
the middle crossbar while the error bars are representative of ± 2 standard deviations from
the mean for n = 5 for each 120s group and n = 10 for each 300s group. The yellow heighted
region indicates the range of maximum log10 reductions that can be achieved based on n =
9 positive samples. B) Efficacy conversion from QPM testing.
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5.3.1.2 Applied Force. Preliminary turbidity testing was used to test applied forces
of 0.5, 1, 2, and 5 N compared to the baseline of 0 N. Turbidity testing showed that 2 N of
force had an increase in disinfection consistency compared to 0 N (Figure 17). The Vial
Cap was 6.15% more effective at 2 N against S. aureus and showed similar disinfection
capabilities against E. coli and P. aeruginosa. The increase in consistency and sterilization
prompted further testing QPM at 2 N.

Figure 17
Applied Force Turbidity Results

Note. Data is representative of the mean ± standard deviation where n = 3 for 0.5N, 1 N,
and 5N groups, n = 5 for each 2 N group, and n = 10 for each 0 N group.
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Results from the QPM revealed that there was an increase in bacterial reduction
consistency for all test specimen at 2 N (Figure 18). There was a 6.30 ± 2.28 log10 reduction
in E. coli, 7.67 ± 0.00 log10 reduction in P. aeruginosa, and 6.37± 2.62 log10 reduction in
S. aureus. This is a 20.83% ± 17.96% increase in efficacy for E. coli, 44.12% ± 20.42%
increase for S. aureus, and 14.33% ± 7.93% increase for P. aeruginosa compared to 0 N.
It can also be observed that there is a decrease in disinfection variability when a force is
applied to the Vial Cap.
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Figure 18
Applied Force QPM Results

Note. A) Bacterial log10 reduction of the Vial Cap at 0 N and 2 N. The mean is represented
by the middle crossbar while the error bars are representative of ± 2 standard deviations
from the mean for n = 5 for each 2 N group and n = 10 for each 0 N group. The yellow
heighted region indicates the range of maximum log10 reductions that can be achieved
based on n = 9 positive samples. B) Efficacy conversion from QPM testing.
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5.3.1.3 Sponge Saturation. Sponge saturations of 0%, 25%, 50%, 75%, 80%, 85%,
and 90% were tested and compared to the baseline of 100% saturation to determine the
threshold of sterilization. Preliminary turbidity testing revealed a significant (p = 0.0029)
decrease in effectiveness at 75% saturation for S. aureus (Figure 19). There was a
significant (p = 0.023) reduction in effectiveness against P. aeruginosa at 25% saturation
and a significant (p < 1E-05) decrease against E. coli at 0% saturation. At 85% sponge
saturation, there was no decrease in effectiveness against S. aureus and consistent
disinfection was maintained compared to 100%. This indicates the threshold of disinfection
at 85% saturation and a significant decrease in effectiveness at 75% saturation.

Figure 19
Sponge Saturation Turbidity Results

Note. Data is representative of the mean ± standard deviation where n = 3 for 0%, 25%,
50%, 80%, and 90% groups, n = 5 for 75% and 85% groups, and n = 10 for each 100%
group. *p < 0.05, ** p < 0.01, *** p < 0.001, compared to 100% sponge saturation
within each respective specimen.
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QPM revealed there was a significant (p = 0.028) decrease in bacterial log10
reduction at 75% saturation for S. aureus (Figure 20). There was a 6.28 ± 2.28 log10
reduction in E. coli, 5.44 ± 2.87 log10 reduction in P. aeruginosa, and 0.51 ± 0.69 log10
reduction in S. aureus. The Vial Cap’s performance significantly decreased for the
disinfection of S. aureus, resulting in an 88.24% ± 19.43% decrease in efficacy compared
to 100% saturation. Alternatively, there was an increase in consistent bacterial log10
reduction at 85% saturation for all test specimen. The Vial Cap had a 7.13 ± 0.00 log10
reduction in E. coli, 7.68 ± 0.00 log10 reduction in P. aeruginosa, and 6.35 ± 2.74 log10
reduction in S. aureus. When compared to the bacterial reduction of S. aureus at 75%
saturation, there was a significant (p = 0.018) increase in the Vial Cap’s ability to disinfect
S. aureus at 85% saturation.
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Figure 20
Sponge Saturation QPM Results

Note. A) Bacterial log10 reduction of the Vial Cap at 100%, 85%, and 75%. The mean is
represented by the middle crossbar while the error bars are representative of ± 2 standard
deviations from the mean for n = 5 for 75% and 85% groups and n = 10 for each 100%
groups. The yellow heighted region indicates the range of maximum log10 reductions that
can be achieved based on n = 12 positive samples. * p < 0.05. B) Efficacy conversion of
QPM testing. * p < 0.05.
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5.3.2 Passive Evaporation
Results from long-term evaporation show that evaporation is evident at the day 1
timepoint. Resulting in an 18.86 ± 4.85% loss in 70% IPA at ambient conditions and 26.52
± 5.30% loss at 37°C conditions (Figure 21). Evaporation at ambient room conditions
decreases overtime while evaporation reaches steady state after about 7 days at 37°C
storage. These results indicate the Vial Cap prototype is impacted by passive evaporation
and must be avoided during testing to ensure the desired sponge saturation is tested.

Figure 21
Passive Evaporation Results

Note. Data is representative of the mean ± standard deviation at each time point where n =
10 for each timepoint at both environment conditions.
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5.3.3 Simulated-Usage
To minimize the influence of long-term evaporation during testing, usage testing
was performed over one hour at five-minute intervals to independently measure the impact
of usage on evaporation. Simulated-usage testing revealed a 7.76 ± 2.80% loss in sponge
saturation at ambient room conditions and an 8.82 ± 1.14% loss at 37°C conditions (Figure
22). Since minimal evaporation was experienced during testing, a simple linear model of
evaporation was assumed to estimate the Vial Cap’s maximum number of uses. Using the
Vial Cap’s threshold of effectiveness at 85% sponge saturation, the estimated maximum
uses at ambient conditions is 25 uses and 20 uses at 37°C conditions.
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Figure 22
Simulated-Usage Evaporation Results

Note. A) Simulated-usage evaporation results. Data is representative of the mean ±
standard deviation at each time point where n = 10 for each timepoint at both environment
conditions. B) Assumed linear model of evaporation for both environmental conditions.
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5.4 Discussion
Baseline testing conditions were needed as comparative data to determine the Vial
Cap’s design criteria. Testing of the Vial Cap’s disinfection time, applied force, and sponge
saturation at this stage of prototyping were necessary to gain an insight into the role of each
design criterion. Baseline testing demonstrated early on that the Vial Cap was the most
effective against the Gram-negative bacteria, E. coli and P. aeruginosa. These results are
translatable to other studies performed with pre-saturated towelettes and other common
surface disinfectants [96], [104]–[106]. For example, in a study comparing disinfectant
towelettes it was observed that the towelettes had a 0.12-0.80 log10 greater reduction
against P. aeruginosa than S. aureus for all tested wipes (n = 11) [106]. The reduced
effectiveness against S. aureus could be related to the bacteria’s ability to survive on
nonporous surfaces and create biofilms that can protect itself from adverse conditions
[107].
Disinfection time was the first design element addressed to determine if the
estimated threshold of disinfection was less than 300 s. Preliminary turbidity testing was
used for bulk testing of the various test conditions to obtain a baseline of disinfection before
more precise quantification with colony-counting. Turbidity testing showed that 120 s was
comparable to the disinfection capability at 300 s for all test specimen. S. aureus serves to
define the benchmark of disinfection for all testing because of its lower efficacy results at
300 s. QPM results showed that there was a decrease in bacterial reduction and increase
variability at 120 s compared to 300 s. The decrease in performance could be attributed to
the reduced contact time that is needed to completely disinfect the vial surface [108]. Since
the Vial Cap is not being marketed as a rapid-use device, the estimated time for disinfection
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could be defined as 300 s or longer. Implementing a longer disinfection time could warrant
a margin of safety (MOS) that ensures the user the cap will provide adequate disinfection
when used for at least its prescribed time.
Applied force was a relevant design consideration for the Vial Cap because there is
a crucial role in the mechanical motion of wiping to yield high effectiveness with presaturated towelettes [102], [108]–[110]. The frequency and exerted force of a wiping action
can profoundly influence the result of surface disinfection [108]. Preliminary turbidity
testing revealed no significant difference between any applied forces. 2 N of force
demonstrated an increase in disinfection consistency and therefore was quantified further.
Results from QPM revealed that there was a decrease is variability at 2 N of force.
Incorporating an applied force in the Vial Cap design could be advantageous to ensure
consistent MDV disinfection. Implementing a closure force to the Vial Cap design could
generate the required applied force. The closure force could be generated through a
snapping or locking mechanism that secures the Vial Cap in place, a design similar to
reusable water bottles.
The impact of passive evaporation on the Vial Cap prototype was quantified to
determine its impact on the timing of experiments. It was observed that the Vial Cap is
greatly impacted by passive evaporation as it experienced a 19-26% loss in disinfectant.
Trends of evaporation observed in 37°C conditions can be attributed to the tendency of
PLA to readily absorb moisture and the environment being fully saturated, permitting the
diffusion of IPA from the sponge [111]. Majority of the Vial Cap’s evaporation can be
attributed to the 3D printed PLA used for rapid prototyping. 3D printing can easily create
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structural defects in an object such as high porosity and poor sealing properties [112].
Therefore, it was crucial that testing occurs immediately after loading a Vial Cap prototype
to minimize the impact of passive evaporation.
Another important design criterion of the Vial Cap was the sponge saturation at
which there is a significant decrease in efficacy. It is expected that as the Vial Cap is used,
there will be disinfectant loss due to evaporation. To mimic this, the Vial Cap was loaded
with varying sponge saturations and tested. Turbidity testing revealed that there was a
significant decrease in effectiveness against S. aureus at 75% sponge saturation. Further
quantification with QPM confirmed the significant decrease in efficacy at 75% saturation
for S. aureus. E. coli and P. aeruginosa also had decreasing disinfection consistencies at
75% sponge saturation. However, comparable results to 100% saturation were achieved
with 85% sponge saturation for all specimen. This estimates that the sponge saturation
threshold is 85% to ensure consistent disinfection is maintained with the current prototype.
To minimize any disinfectant loss due to passive evaporation, simulated-usage
testing was performed over a period of 60 min. Usage testing revealed a 7-8% loss in
disinfectant depending on the storage conditions. This loss can be attributed to the exposure
of the saturated sponge surface area to the environment. When correlating this to efficacy,
the Vial Cap has an estimated maximum of 25 uses in ambient storage conditions and 20
in 37°C conditions. This procedure can be used to determine the final Vial Cap’s lifespan,
important information required by the FDA for the device’s instructions for use (IFU)
[113]. Additionally, the long-term evaporation procedure described can serve to test the
Vial Cap’s shelf-life and the integrity of packaging as per FDA requirements [114].
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Results from testing revealed a major design flaw with the Vial Cap’s susceptibility
to evaporation. Evaporation during usage is expected and has a minimal impact on the
present disinfectant compared to long-term storage. Evaporation can be mitigated through
selection of manufacturing processes that are not susceptible to creating high porosity.
Precision injection molding offers a potential solution to significantly reduce the Vial
Cap’s susceptibility to evaporation. Since this manufacturing process is not additive like
3D printing, it has the ability to mold an object with a high tolerance for precision and
minimal porosity [115]. Incorporation of recommended design elements and production
with methods less prone to porosity can increase the Vial Cap’s efficacy for safe and
effective use.
5.5 Conclusion
Mounting evidence of MDV contamination in healthcare settings has identified a
user compliance issue with the current disinfection protocol [8]. The Vial Cap offers a
potential solution to this issue as it continuously disinfects the vial. The efficacy of different
design elements was quantified using a modified version of ASTM Standard E2362-15 to
provide a direct comparison to pre-saturated wipes. Results of efficacy testing were used
to determine important elements of the Vial Cap design that yielded the most reliable
disinfection capabilities. The disinfection time, applied force, maximum uses were
estimated from efficacy testing. The disinfection time and maximum uses are to be
incorporated in the IFU to provide the user with clear information for the safe and effective
use of the Vial Cap. Quantifying the applied force served to demonstrate the significance
of mechanical pressures for disinfection.
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Design improvements attained from efficacy testing can improve the Vial Cap’s
ability to consistently achieve 100% bacterial reduction for the tested nosocomial
pathogens as well as other virulent ones such as MRSA, Clostridium difficile, and
vancomycin-resistant enterococci [116]. Future iterations of the device will continue to
undergo the testing methods described in this work to define the Vial Cap’s efficacy. With
the proper design changes, the Vial Cap has the potential to reduce user-related errors with
MDV disinfection and increase patient safety.
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Chapter 6
Project Summary and Future Work
6.1 Project Summary
The aims of this research were to evaluate the usability and efficacy of the Vial Cap
through iterative experimental methods that can be used in final testing of the device. HFE
design techniques were utilized for determining the user needs, design flaws, and to assess
the device’s usability [11], [69]. The Vial Cap’s ease of use, efficiency, and user acceptance
were measured through a usability test with the intended users. Results from usability
testing revealed that the Vial Cap had high learnability, acceptability, and usability. Such
successful testing results give an indication of the perceived usefulness and acceptance of
the current prototype as well as feedback for design improvement [83], [89].
Evaluation of the Vial Cap’s efficacy was a critical element to offer evidence that
the device is as effective as pre-saturated wipes used in the current protocol. For the
purposes of this research, the disinfection time, applied force, and maximum uses were
investigated to determine their impact on effectiveness. Results provided the estimated
disinfection time and prescribed uses needed to ensure consistent sterilization. Design
considerations such as adding an applied force were also noted to improve disinfection
consistency. Efficacy testing provides valuable insight into the current state of the Vial Cap
prototype and recommendations for final design changes. The impact of this research
identified the need for improved MDV disinfection methods that are less susceptible to
user-error. With improvements to the device design and manufacturing materials, the Vial
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Cap can prove to be an advantageous solution to this issue and improve overall patient
care.
6.2 Future Work
These results are the first to identify the potential of the Vial Cap as a new method
of MDV disinfection. The methods outlined in this research can be used to evaluate future
iterations of the Vial Cap design. Potential avenues forward with the Vial Cap would be
testing its effectiveness against other more virulent nosocomial pathogens such as MRSA,
Clostridium difficile, Canadian albicans, and viruses such as adenoviruses [101]. The Vial
Cap also have the potential to be marketed for at-home patients and caregivers. A similar
usability test could be given to these individuals to determine if the practicality of the Vial
Cap for patients who give self-injections. An additional design consideration could be the
incorporation of a wiping motion in the Vial Cap application. In addition to pressure,
literature suggests the importance of a mechanical wiping motion to effectively remove
microbial contamination on a hard surface [96], [108]. The results from this research also
provide guidance for the selecting the proper packaging that prevents passive evaporation.
Overall, the impact of this research allows for the continual testing of the Vial Cap to better
its performance for implantation into the healthcare field that will ultimately improve
infection control practices and patient care.
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Appendix A
SUS Questionnaire
Please check the box that reflects your immediate response to each statement. Don’t think too
long about each statement. Make sure you respond to every statement. If you don’t know how
to respond, simply check box “3.”
Strongly
Strongly
Disagree
Agree
1. I think that I would like to use this product frequently.

1

2

3

4

5

2. I found the product unnecessarily complex.

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

5. I found the various functions in the product were well
integrated.

1

2

3

4

5

6. I thought there was too much inconsistency in this
product.

1

2

3

4

5

7. I imagine that most people would learn to use this
product very quickly.

1

2

3

4

5

8. I found the product very awkward to use.

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

3. I thought the product was easy to use.
4. I think that I would need the support of a technical
person to be able to use this product.

9. I felt very confident using the product.
10. I needed to learn a lot of things before I could get
going with this product.

11. Overall, I would rate the user-friendliness of this product as:

Worst
Imaginable

Awful

Poor

OK
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Good

Excellent

Best
Imaginable

Appendix B
Additional Participant Feedback
Table B1
Participant Feedback
Comment
Positive (n = 1)

Negative (n = 1)

Reduces confusion

Top heavy design

Vial Cap allows for easier grip of vial

Skeptical of disinfection, would still use
IPA wipe after removal of Vial Cap

Could be cost-effective in the long-term

Hinge is bulky

Liked clicking sound of plastic when
sealing Vial Cap to ensure it is closed

Prefer cap to be a flexible material
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